A

Agilent Technologies, Inc.

$134.29 +0.70 (+0.52%) At close · Jul 10

Market Cap

$37.93B

282,431,944

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$6.95B +6.7%

FY2025

Net Income

$1.3B +1.1%

FY2025

Gross Margin

52.43% -1.9pp

FY2025

Operating Margin

21.29% -1.6pp

FY2025

Diluted EPS

$4.57 +3.2%

FY2025

Operating Cash Flow

$1.56B -11%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+0.5%	+5.4%	+5.6%	$7.23B	$6.95B	$6.51B	$6.83B	$6.85B	$6.32B	$5.34B	$5.16B	$4.91B	$4.47B	$4.2B	$4.04B	$4.05B	$3.89B	$6.86B	$6.62B	$5.44B	$4.48B	$5.77B	$5.42B
Cost of Revenue	+1.9%	+5.7%	+5.2%	$3.42B	$3.31B	$2.98B	$3.37B	$3.13B	$2.91B	$2.5B	$2.36B	$2.23B	$2.06B	$2.01B	$2B	$2.07B	$1.99B	$3.25B	$3.09B	$2.51B	$2.19B	$2.58B	$2.45B
Gross Profit	-0.7%	+5.1%	+6.0%	$3.81B	$3.64B	$3.54B	$3.47B	$3.72B	$3.41B	$2.84B	$2.81B	$2.68B	$2.41B	$2.2B	$2.04B	$1.98B	$1.91B	$3.6B	$3.53B	$2.93B	$2.29B	$3.2B	$2.97B
Gross Margin	—	—	—	—	52.43%	54.3%	50.71%	54.35%	53.92%	53.14%	54.33%	54.54%	53.87%	52.28%	50.54%	48.81%	48.97%	52.55%	53.35%	53.82%	51.15%	55.35%	54.78%
Research & Development	-0.9%	-1.7%	+3.3%	$473M	$455M	$479M	$481M	$467M	$441M	$495M	$404M	$387M	$341M	$329M	$330M	$358M	$337M	$668M	$649M	$612M	$642M	$704M	$685M
Selling, General & Administrative	+1.4%	+2.7%	+3.7%	$1.79B	$1.71B	$1.57B	$1.63B	$1.64B	$1.62B	$1.5B	$1.46B	$1.39B	$1.25B	$1.25B	$1.19B	$1.2B	$1.18B	$1.82B	$1.81B	$1.75B	$1.6B	$1.7B	$1.7B
Amortization of Intangibles	-18.2%	-10.8%	-4.0%	$88M	$105M	$105M	$140M	$192M	$195M	$186M	$128M	$110M	$120M	$154M	$158M	$189M	$190M	$136M	$111M	$76M	$45M	$53M	—
Depreciation & Amortization	-3.1%	-1.3%	+1.3%	—	$288M	$257M	$271M	$317M	$321M	$308M	$238M	$210M	$212M	$246M	$253M	$384M	$372M	$301M	$253M	$202M	$162M	$201M	$191M
Restructuring Charges	—	—	+29.9%	$53M	$82M	$76M	$46M	—	—	—	—	—	—	—	$6M	$68M	$53M	$0	$2M	$64M	$252M	$0	—
Total Costs & Expenses	+1.5%	+4.0%	+4.5%	$5.68B	$5.47B	$5.02B	$5.48B	$5.23B	$4.97B	$4.49B	$4.22B	$4.01B	$3.67B	$3.59B	$3.52B	$3.63B	$3.51B	$5.74B	$5.54B	$4.88B	$4.43B	$4.98B	—
Operating Income	-2.9%	+11.8%	+11.0%	$1.56B	$1.48B	$1.49B	$1.35B	$1.62B	$1.35B	$846M	$941M	$904M	$807M	$615M	$522M	$419M	$386M	$1.12B	$1.07B	$566M	$47M	$795M	$584M
Operating Margin	—	—	—	—	21.29%	22.86%	19.76%	23.63%	21.32%	15.85%	18.23%	18.4%	18.05%	14.64%	12.93%	10.35%	9.91%	16.32%	16.19%	10.4%	1.05%	13.77%	10.77%
EBITDA	-3.0%	+8.9%	+8.6%	—	$1.77B	$1.75B	$1.62B	$1.94B	$1.67B	$1.15B	$1.18B	$1.11B	$1.02B	$861M	$775M	$803M	$758M	$1.42B	$1.32B	$768M	$209M	$996M	$775M
Interest Expense	+10.1%	+7.5%	+5.4%	$105M	$112M	$96M	$95M	$84M	$81M	$78M	$74M	$75M	$79M	$72M	$66M	$110M	$107M	$101M	$86M	$96M	$88M	$123M	—
Interest Income	+90.3%	+50.6%	+24.4%	$61M	$62M	$80M	$51M	$9M	$2M	$8M	$36M	$38M	$22M	$11M	$7M	$9M	$7M	$9M	$14M	$20M	$29M	$113M	$172M
Other Non-Operating Income	—	-38.1%	-9.9%	$69M	$6M	$49M	$33M	-$39M	$92M	$66M	$16M	$79M	$53M	-$10M	$17M	-$89M	$7M	$16M	$33M	$70M	$19M	$30M	$5M
Equity in Earnings of Unconsolidated Entities	—	—	—	—	—	—	—	—	—	—	—	$0	$0	-$10M	-$9M	-$7M	-$2M	—	—	—	—	—	—
Pretax Income	-1.6%	+11.3%	+6.5%	$1.58B	$1.44B	$1.52B	$1.34B	$1.5B	$1.36B	$842M	$919M	$946M	$974M	$859M	$767M	$763M	$732M	$1.38B	$1.31B	$938M	$391M	$815M	$670M
Income Tax	-19.2%	+1.4%	+12.1%	$166M	$132M	$232M	$99M	$250M	$150M	$123M	-$152M	$630M	$119M	$82M	$42M	-$3M	$68M	-$110M	$20M	$8M	$38M	$122M	$32M
Net Income	+1.3%	+12.6%	+12.5%	$1.41B	$1.3B	$1.29B	$1.24B	$1.25B	$1.21B	$719M	$1.07B	$316M	$684M	$462M	$401M	$549M	$734M	$1.15B	$1.01B	$684M	-$31M	$693M	$638M
Net Margin	—	—	—	—	18.75%	19.8%	18.15%	18.31%	19.15%	13.47%	20.74%	6.43%	15.3%	10.99%	9.93%	13.56%	18.85%	16.81%	15.3%	12.56%	-0.69%	12%	11.77%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$7M	$3M	—
Comprehensive Income	+5.1%	+14.2%	+60.7%	—	$1.38B	$1.31B	$1.26B	$1.19B	$1.45B	$711M	$972M	$254M	$841M	$350M	$12M	$124M	$936M	$926M	$1.22B	$781M	-$38M	$107M	$890M
EPS (Basic) USD/shares	+3.1%	+14.5%	+14.4%	—	$4.59	$4.44	$4.22	$4.19	$3.98	$2.33	$3.41	$0.98	$2.12	$1.42	$1.20	$1.65	$2.15	$3.31	$2.92	$1.97	-$0.09	$1.91	$1.62
EPS (Diluted) USD/shares	+3.0%	+14.7%	+14.3%	—	$4.57	$4.43	$4.19	$4.18	$3.94	$2.30	$3.37	$0.97	$2.10	$1.40	$1.20	$1.62	$2.13	$3.27	$2.85	$1.94	-$0.09	$1.87	$1.57
Shares Outstanding (Basic Avg) shares	-1.7%	-1.7%	-1.6%	—	284M	290M	294M	299M	304M	309M	314M	321M	322M	326M	333M	333M	341M	348M	347M	347M	346M	363M	394
Shares Outstanding (Diluted Avg) shares	-1.7%	-1.8%	-1.6%	—	285M	291M	296M	300M	307M	312M	318M	325M	326M	329M	335M	338M	345M	353M	355M	353M	346M	371M	406

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $11.87B in buybacks, $2.82B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Diagnostics & Research median 2.92×

EV/EBIT

—

Diagnostics & Research median 31.02×

P/E (TTM)

26.97×

Diagnostics & Research median 32.16×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31
Agilent CrossLab	$2,908,000,000	$2,747,000,000	$2,656,000,000	$1,452,000,000	$1,360,000,000	$1,177,000,000	$1,840,000,000	$1,701,000,000
Life Sciences and Diagnostics Markets	$2,726,000,000	$2,466,000,000	$2,780,000,000	—	—	—	—	—
Applied Markets	$1,314,000,000	$1,297,000,000	$1,397,000,000	—	—	—	—	—
Diagnostics and Genomics	—	$1,651,000,000	$1,755,000,000	$1,766,000,000	$1,296,000,000	$1,047,000,000	$1,021,000,000	$943,000,000
Life Sciences and Applied Markets	—	$3,215,000,000	$3,510,000,000	$3,630,000,000	$3,663,000,000	$3,115,000,000	$2,302,000,000	$2,270,000,000

By Geography (USD)

Component	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31
Rest of World	$3,382,000,000	$3,047,000,000	$3,040,000,000	$2,964,000,000	$2,887,000,000	$2,500,000,000	$2,525,000,000	$2,485,000,000
United States	$2,342,000,000	$2,246,000,000	$2,410,000,000	$2,385,000,000	$2,159,000,000	$1,752,000,000	$1,619,000,000	$1,414,000,000
China	$1,224,000,000	$1,217,000,000	$1,383,000,000	$1,499,000,000	$1,273,000,000	$1,087,000,000	$1,019,000,000	$1,015,000,000

By Product & Service (USD)

Component	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31
Non Instrumentationand Other	$4,521,000,000	$4,156,000,000	$4,091,000,000	$3,941,000,000	$3,662,000,000	$3,090,000,000	$3,013,000,000	—
Instrumentation	$2,427,000,000	$2,354,000,000	$2,742,000,000	$2,907,000,000	$2,657,000,000	$2,249,000,000	$2,150,000,000	—
Product	—	—	—	—	—	—	—	$3,746,000,000
Service Other	—	—	—	—	—	—	—	$1,168,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31
Agilent CrossLab	$946,000,000	$925,000,000	$839,000,000	$370,000,000	$323,000,000	$272,000,000	$475,000,000	$388,000,000
Life Sciences and Diagnostics Markets	$536,000,000	$484,000,000	$673,000,000	—	—	—	—	—
Applied Markets	$301,000,000	$312,000,000	$363,000,000	—	—	—	—	—
Diagnostics and Genomics	—	$320,000,000	$363,000,000	$390,000,000	$273,000,000	$192,000,000	$185,000,000	$173,000,000
Life Sciences and Applied Markets	—	$877,000,000	$1,049,000,000	$1,097,000,000	$1,017,000,000	$792,000,000	$542,000,000	$543,000,000
Segment Total	—	—	—	$1,857,000,000	$1,613,000,000	$1,256,000,000	$1,202,000,000	$1,104,000,000

Operating Margin by Segment (%)

Component	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31	2020-10-31	2019-10-31	2018-10-31
Agilent CrossLab	32.5%	33.7%	31.6%	25.5%	23.8%	23.1%	25.8%	22.8%
Life Sciences and Diagnostics Markets	19.7%	19.6%	24.2%	—	—	—	—	—
Applied Markets	22.9%	24.1%	26%	—	—	—	—	—
Diagnostics and Genomics	—	19.4%	20.7%	22.1%	21.1%	18.3%	18.1%	18.3%
Life Sciences and Applied Markets	—	27.3%	29.9%	30.2%	27.8%	25.4%	23.5%	23.9%

Key facts CIK 1090872 CUSIP 00846U101 13F (30d) 79 filings 49 filers Visit website Investor relations